Ipratropiu/Salbutamol Cipla (Salbutamol, Ipratropium Bromide Monohydrate)

Ipratropium bromide blocks muscarinic receptors in the airway smooth muscle, preventing acetylcholine‑induced constriction. Salbutamol selectively stimulates β2‑adrenergic receptors, increasing cyclic AMP and causing smooth‑muscle relaxation. Together they produce a synergistic bronchodilatory effect that rapidly improves airflow.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Typically the medication is administered via a nebulizer or inhaler device as directed by a healthcare professional, and patients should follow the prescriber’s instructions precisely.

Safety data for ipratropium bromide and salbutamol during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Clinicians are advised to discuss individual risk factors with the patient before prescribing.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

The ipratropium‑salbutamol combination offers both anticholinergic and β2‑agonist actions in a single inhalation, providing faster and more comprehensive bronchodilation than monotherapy with either agent alone. Compared with long‑acting combinations, it is typically used for acute relief rather than maintenance therapy.

The inhalation solution should be stored at room temperature, below 25 °C, in its original container. Protect it from moisture, direct sunlight, and extreme temperatures. Do not freeze the product, and keep the mouthpiece clean to maintain dose accuracy.

The medication is delivered by inhalation, usually via a nebulizer or a metered‑dose inhaler (MDI) as prescribed. Patients should inhale the full dose, hold their breath briefly if instructed, and rinse their mouth after use to reduce irritation and potential oral thrush.

Serious adverse events include paradoxical bronchospasm, which can worsen breathing, and cardiovascular effects such as arrhythmias or severe tachycardia. Rarely, patients may experience anaphylactic reactions or angioedema. Immediate medical attention is required if any of these symptoms occur.

The product is contraindicated in individuals with known hypersensitivity to ipratropium, salbutamol, or any formulation excipients. It should also be avoided in patients with certain cardiac conditions where β2‑agonist stimulation could be hazardous, unless specifically directed by a physician.